NCT04177290View on ClinicalTrials.gov

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

September 4, 2022

Conditions
Advanced or Metastatic NSCLC
Interventions
DRUG

Sintilimab (M1b)

Intravenous infusion

DRUG

Sintilimab (approved)

Intravenous infusion

Trial Locations (1)

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04177290 - A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients | Biotech Hunter | Biotech Hunter